and 420rag as an aqueous solution (N = 100).
INTRODUCTION
Ibuprofen, 2-(4-isobutylphenyl)-propionic acid, is widely used in the treatment of rheumatoid arthritis and osteoarthroses. Mills et al. (1) reported that ibuprofen at a concentration of 20/xg/ml was 99% bound in whole human plasma. Whitlam et al. (2) and Kober and Sj6holm (3) studied the binding of ibuprofen to human serum albumin by the equilibrium dialysis method, while Whitlam and Brown (4) reported data on the binding of ibuprofen to 4% bovine serum albumin, 1% human serum albumin, and one sample of whole human serum by the ultrafiltration method. Wanwimolruk et al. (5) reported postdialysis serum free fraction for ibuprofen at a total concentration of 40 mg/L for 10 patients with rheumatoid arthritis and 10 patients with osteoarthritis. The human study discussed in this series of articles was designed to elucidate the cause of the nonlinear relationship between area under the total (bound+free) ibuprofen plasma concentration-time curve and the administered dose of the drug. It was found that the area under the free (unbound) plasma concentration-time curve was a linear function of dose, and hence the nonlinearity in the case of total drug was attributed to the nonlinear plasma protein binding. The area-dose relationships are reported in another article (6) . We report here in detail the results of the plasma protein binding studies and thus provide a considerable amount of data on the plasma protein binding of ibuprofen in the presence of its metabolites and in whole human plasma under conditions of use of the drug in man.
EXPERIMENTAL PROCEDURE

Human Study
Fifteen healthy nonobese male volunteers with no known disease were selected. The average and range were: 25 (22-35) years, 78.2 (71.7-92.5) kg, and 2.01 (1.89-2.24)m 2 body surface area. Normal complete physical examination, routine blood and urinalysis, and normal values for kidney and liver function tests were necessary for entry into the study. Informed consent was obtained from each subject. All subjects participating in the study received no barbiturates or other enzyme-inducing agents for a period of 30 days preceding initiation of the study and none concurrent with it. They received no other medication or alcoholic beverages for a period of 7 days before initiation of the study and none during the study.
Treatments A, B, and C were as follows: A, One 400 mg ibuprofen tablet4; B, two 400 mg ibuprofen tablets; C, three 400 mg ibuprofen tablets. The tablets were assayed at 401 mg/tablet; hence doses were 401,802, and 1203 mg ibuprofen for treatments A, B, and C, respectively. Treatment D was 20 ml of an oral solution of ibuprofen, 20 mg/ml; the solution was assayed at 21.0 mg/mi; hence the dose was 420mg of ibuprofen. The treatment schedule is shown in Table I . Subjects received treatments A, B, and C in crossover fashion in weeks 1 to 3; then all subjects received 4Courtesy of C. C. T. Motrin (The Upjohn Company). Subjects fasted overnight (from 10 p.m.) and for 4 hr after dosing. For treatments A, B, and C, 5 ml of blood was collected by venipuncture at 0, 0.167, 0.333, 3, 10, and 12 hr, and 10 ml was collected at 0.5, 1, 1.5, 2, 4, 6, and 8 hr. For treatment D, 5 ml of blood was collected at 0, 0.0833, 0.167, 0.25, 0.333, and 3 hr, and 10 ml was collected at 0.5, 1, 1.5, 2, 4, 6, and 8 hr.
Assay of Plasma and Plasma Protein Binding
Aliquots of all plasma samples were assayed for unchanged ibuprofen by a sensitive and specific HPLC method (7) . Atiquots of plasma obtained from the 10 ml blood samples were used in plasma protein binding studies. A 1 ml volume of plasma was dialyzed against a 3 ml volume of phosphate buffer (0.693 g dibasic potassium phosphate, 0.138 g monobasic sodium phosphate, 2.25 g sodium chloride, made up to 500 ml with water then adjusted to pH 7.4). The dialysis membrane was Spectrapor | 2 tubing (Spectrum Medical Industries, Los Angeles, Calif.) having a flat width of 10 ram. The tubing was cut into lengths of 15 cm, soaked in water for 10 min, and then in methanol for an additional 10 rain. Following the methanol soak the membrane was thoroughly washed with distilled water (5 changes) and was then soaked in the dialysis buffer for at least 1 hr before use. Prior to dialysis the tubing was removed from the buffer, and excess buffer was gently wiped off. One end of the tube was firmly tied with string, then 1 ml of plasma spiked with a suitable amount of radioactive ibuprofen was carefully introduced into the open end. The open end was tied with string, and the tube was folded in a U-shape and placed inside a 1.5 x 10 cm test tube containing 3 ml of phosphate buffer. The tops of the tubes were sealed with parafilm to minimize buffer loss due to evaporation. The tubes were placed in racks in a light-tight shaking water bath set at 37~ Dialysis was allowed to proceed for 8 hr, shown to be the time necessary for equilibration. At the end of the dialysis period the tubing was removed from the buffer, gently dried on the outside, then inverted 10 times to ensure adequate mixing of the contents. One end of the tubing was cut, and a 100 ,al aliquot of the dialyzed plasma was added to 15 ml of ACS scintillation fluid (American Corp., Arlington Heights, I11.) along with 900 ~1 of water. To a scintillation vial containing the same scintillation cocktail was added 2 ml of the buffer from the same dialysis tube. The contents of the vials were thoroughly mixed and were counted for 10 rain in a Beckman LS7500 Scintillation Counter (Beckman Instruments, Fullerton, Calif.). The counts obtained were corrected for background and quenching effects.
The radioactive ibuprofen was 2-(4-isobutylphenyl)- [3-14C] propionic acid with a specific activity of 22.6 ~Ci mg -1 and was radiochemically pure. A stock solution was prepared such that when 10 ~1 of this solution was added to 1 ml of plasma, the counts obtained were in the region of 50,000 dpm/ml.
For calculating the free (Crd) 5 and bound (Cbd) drug concentrations at dialysis equilibrium, the method outlined recently by Tozer (8) was employed. This method is independent of volume changes that may occur in dialysis systems due to the osmotic movement of water (9) . The free fraction at dialysis equilibrium, f~, was obtained as the ratio C1d/(C1d + Cbd).
Since drug is lost from the protein compartment during dialysis, the values of fd and the total drug concentration (C~a=Qd+Qd) do not correspond to the values of the original plasma sample before dialysis. Correction back to this original C, has been discussed previously by Behm and Wagner (10) . In this study the estimation of the free (C r) and bound (Cb) drug concentrations corresponding to Ct was carried out as follows.
Pooled Cry, Cba data for each subject (25-28 data points, 5-7 data points from each of four phases) were computer-fitted to the Scatchard equation (11) (2) and substituting Eq. Thus, knowing the values of P(1) and P(2) for any subject enables you to solve Eq. (4) at any desired Ct and obtain a value of Cj. as the positive root of the equation. Ch is then simply found as the difference between (7, and G.
The bound/free ratio, Cb/C r, is related to the free fraction, f= G/(G+C0, by Eq. (5):
Five sets of binding data were evaluated to determine whether the bound/free ratios or the free fractions were normally distributed. Statistical analysis was performed using the MIDAS statistical package (13) . The first four sets of data were Cbd/Cfd and fd at dialysis equilibrium following treatments A, B, C, and D. The fifth set consisted of the pooled Cb/C r and f for treatments A-D corrected back to the corresponding plasma concentration as the blood was withdrawn from the subjects. The pooled data consisted of N=419 samples. Treatments A, B, C, and D consisted of N = 102, 100, 104, 100, respectively. The discrepancy between the dialysis equilibrium and pooled sample sizes is due to the fact that 13 plasma dialysis samples were either lost or contaminated. However, it was still possible to estimate Cb and C i values at these time points since the Ct values were known.
RESULTS
Cumulative probability plots corresponding to the free fraction data at dialysis equilibrium for treatments A, B, C, and D are shown in Fig. 1 . The plots are all curved indicating skewness and nonnormality. Cumulative probability plots corresponding to the bound/free ratio data at dialysis equilibrium are shown in Fig. 2 . In all cases the plots are linear over most of the range indicating that the data are normally distributed.
A summary of the percent free fraction and bound/free ratio data corresponding to the C, values as blood was withdrawn from the subjects is presented in Tables II and III, respectively. Cumulative normal probability plots for the pooled (N = 419) Cb/Cy and f data are shown in Fig. 3 . Again the bound/free ratios appear normally distributed, while the free fractions appear skewed and nonnormal. The Lilliefors test (14), which is an extension of the KolmogorovSmirnov test for normality, was also performed on the above mentioned data. The results of these tests suggest that the bound/free ratio indeed fits the normal distribution assumption more closely than the free fraction in most instances. The distributions of the bound/free ratio at dialysis equilibrium gave the following results. Treatment A was significantly different from a normal distribution (p<0.05), but treatments B, C, and D were not significantly different from a normal distribution ( p > 0.5). The distributions corresponding to the free fraction at dialysis equilibrium for treatments A and C were highly significantly different from a normal distribution (p< 0.01), whereas treatments B and D were significantly different at a more conservative test level (p < 0.08 and p < 0.14, respectively). When the test procedure was performed on the pooled Cb/C I and f data, the distribution of bound/free ratios was not significantly different than a normal distribution (p > 0.3), whereas the free fraction was significantly different (p<0.01). Thus, on the basis of two approaches used to investigate normality, the distributions of the bound/free ratio approximate the normal whereas the distributions of the free fractions do not. The authors believe that the shape of the cumulative distribution plot is much more informative concerning normality or nonnormality than many of the statistical tests in the literature.
By plotting data for individual subjects, as illustrated by Fig. 4 for subject 14, the relationship between bound and free concentrations for a given subject appeared to be independent of the treatment; hence data following treatments A, B, C, and D for each subject were pooled (25 to 28 points per subject). Each of these pooled data sets were computer-fitted to Eq. (1). Results are listed in Table IV . The fits of the 15 sets of data to the Scatchard equation with only one class of binding sites were excellent Table IV ).
considerable literature data on the binding of ibuprofen in vitro to human and bovine serum albumin (2) (3) (4) 15) , there has been little data reported on the binding of the drug in vivo to serum or plasma (1, 4, 5, 15 (Table IV) It should be noted that with the experimental methods employed, the concentrations Cb and C r, upon which the binding parameters, % free, and bound/free ratio are based, refer to those existing in plasma as the blood was withdrawn from the subjects. Appropriate corrections were made both for volume changes in the compartments and loss of ibuprofen from the protein compartment during dialysis; hence our data are truly in vivo binding data. In the present paper distributional analysis has been performed both with corrected Cb, C I data and with experimentally obtained Cb~, Cye dialysis data. The postdialysis data and the corrected data have similar shaped distributions suggesting that the normality of the bound/free ratios and the skewness of the free fraction are real observations and not an artifact of the mathematical method used to back-calculate concentrations corresponding to the original C, values.
Although free fraction and percent free or percent bound are used widely as protein binding parameters, we have found that the free fraction of ibuprofen is not normally distributed in five different populations each with 100 to 419 values. However, the reciprocally related (Eq. 3) bound/free ratio was normally distributed for the corresponding five populations. This suggests that tests for significance of difference of population means should more appropriately be carried out using the bound/free ratios rather than the free fractions.
Although we have performed distributional analysis with dialysis equilibrium data in this paper, we would like to stress the importance of expressing bound and free drug concentrations relative to the measured total plasma concentrations. The methods outlined here and elsewhere (8, 10) provide methods to perform these corrections.
APPENDIX 1: DEFINITION OF SYMBOLS
C, Total drug concentration in plasma before dialysis C,d Total drug concentration in plasma at dialysis equilibrium C I Free drug concentration in plasma before dialysis Crd Free drug concentration in plasma at dialysis equilibrium Cb Bound concentration in plasma before dialysis Cbd Bound concentration in plasma at dialysis equilibrium which would have been observed if no volume change had occurred C* Concentration of radiolabeled drug in plasma prior to dialysis (mass/volume) D* Concentration of labeled drug in plasma prior to dialysis (dpm/ml) D*, Concentration of free labeled drug in the buffer compartment at dialysis equilibrium (dpm/ml) Free fraction in plasma before dialysis Free fraction in plasma at dialysis equilibrium Association constant of the drug-protein complex if one assumes the drug was bound to only one protein. This is most probably an apparent value since the authors believe that the binding was to more than one entity. Equation (1) adequately describes the binding of ibuprofen in an empirical sense. P(1) and P (2) 
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